We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Cartridge-Based Antigen Testing System Delivers PCR Equivalent Performance at Half the Price

By LabMedica International staff writers
Posted on 19 May 2023

A new first-in-class diagnostic platform technology that is transitioning from a working prototype to a commercial system is soon set to disrupt the point-of-care diagnostics industry. More...

Zymo Research (Irvine, CA, USA) has joined hands with Burst Diagnostics (Fort Collins, CO, USA) to create a pioneering diagnostic platform technology. This first-in-class diagnostic platform technology has the potential to deliver unmatched sensitivity and never-seen-before multiplexing abilities in antigen-based point-of-care testing. The platform is based on a novel microfluidic cartridge that is capable of miniaturizing and integrating all the traditional steps commonly carried out in a clinical lab environment (including washing and signal amplification) into a compact, sturdy, and electricity-free hand-held device.

The cartridge-based antigen testing system promises performance on par with PCR-based testing but at half the cost. The ELISA system bears a striking resemblance to a rapid antigen test but comes with an integrated high-sensitivity chemiluminescence reader. Burst plans to offer rapid immunoassays with fewer false negatives than standard rapid antigen tests used in point-of-care situations while also providing these results at lower costs than lab-based tests. Burst is planning further studies and is aiming to submit an application for authorization from the US Food and Drug Administration for its inaugural test and reader by the first quarter of 2024. The company's first offering is likely to be a multiplex test for COVID-19, influenza A and B, and RSV. Additionally, Burst is in the initial stages of developing tests for sexually transmitted infections and strep throat.

"The tests we are building are simple, convenient, and inexpensive like rapid antigen tests but capable of producing laboratory-quality data with the level of sensitivity and accuracy previously exclusive to central lab run tests," said Dr. Charles Henry, Founder and CEO of Burst Diagnostics.

"We have a radical new technology and with it, we will challenge the limitations associated with antigen tests as we know them," added Dr. Rose Nash, Chief Operating Officer and Scientist at Burst Diagnostics.

"The creation of this advanced and ultra-sensitive technology will transform the industry and significantly impact the healthcare sector. It will enable faster and more precise diagnosis and treatment of diseases," said Dr. Larry Jia, Founder and CEO of Zymo Research.

Related Links:
Zymo Research
Burst Diagnostics 


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automatic Hematology Analyzer
LABAS F9000
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.